Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Raw Materials (2023 - 2025)

MDxHealth has reported Raw Materials over the past 3 years, most recently at $6.9 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 78.26% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $6.9 million, up 78.26%, while the annual FY2025 figure was $6.9 million, 78.26% up from the prior year.
  • Raw Materials was $6.9 million for Q4 2025 at MDxHealth, up from $3.9 million in the prior quarter.
  • Across five years, Raw Materials topped out at $6.9 million in Q4 2025 and bottomed at $2.8 million in Q4 2023.
  • The 3-year median for Raw Materials is $3.9 million (2024), against an average of $4.5 million.
  • Year-over-year, Raw Materials surged 39.22% in 2024 and then soared 78.26% in 2025.
  • Over 3 years, Raw Materials stood at $2.8 million in 2023, then surged by 39.22% to $3.9 million in 2024, then soared by 78.26% to $6.9 million in 2025.
  • The last three reported values for Raw Materials were $6.9 million (Q4 2025), $3.9 million (Q4 2024), and $2.8 million (Q4 2023) per Business Quant data.